Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

We do still transplant CML, don't we?

Charles F Craddock1

  • 1Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.

Hematology. American Society of Hematology. Education Program
|December 4, 2018
PubMed
Summary

Tyrosine kinase inhibitors have transformed chronic myeloid leukemia (CML) treatment. Allogeneic stem cell transplantation (allo-SCT) remains crucial for TKI-resistant or advanced CML, with improving outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.

EJHaem·2022
Same author

Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2018
Same author

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Clinical cancer research : an official journal of the American Association for Cancer Research·2017
Same author

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.

Blood·2015
Same author

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Haematologica·2014
Same author

Subsequent donation requests among 2472 unrelated hematopoietic progenitor cell donors are associated with bone marrow harvest.

Haematologica·2013

Area of Science:

  • Hematology
  • Oncology
  • Transplant Medicine

Background:

  • Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment, improving patient survival.
  • Allogeneic stem cell transplantation (allo-SCT) is now reserved for specific CML cases, unlike its previous central role.

Purpose of the Study:

  • To evaluate the evolving role of allo-SCT in CML management.
  • To discuss advancements in transplant technology and their impact on CML treatment outcomes.
  • To highlight strategies for mitigating transplant failure and disease relapse in CML patients.

Main Methods:

  • Review of clinical activity and outcomes of TKIs and allo-SCT in CML.
  • Analysis of factors influencing transplant success, including patient fitness, HLA disparity, and conditioning regimens.
  • Examination of advances in conditioning regimens and post-transplant therapies.

Main Results:

  • Allo-SCT is now primarily for TKI-resistant chronic-phase or advanced-phase CML.
  • Reduced intensity conditioning and increased donor availability have expanded transplant options.
  • Understanding patient-specific factors allows for personalized transplant decisions.
  • Advances in conditioning and post-transplant therapies reduce relapse risk.

Conclusions:

  • Allo-SCT remains a vital, potentially curative option for selected CML patients.
  • Personalized decision-making and therapeutic advancements are key to improving transplant outcomes.
  • The role of stem cell transplantation (SCT) in CML management is expected to increase due to rising prevalence and improved outcomes.

Related Experiment Videos